Tranexamic acid and its use in early pregnancy; a scoping review.

Authors

Chung Bethany, Santiapillai Georgina, Memtsa Maria, Abdul-Kadir Rezan

Published in

Thrombosis research. Volume 265. Pages 109811. Aug 25, 2026. Epub Aug 25, 2026.

Abstract

Bleeding in early pregnancy is reported in 1 in 4 of pregnancies and is linked to increased risks of miscarriage, preterm birth, low birth weight, placental abruption, and stillbirth. Current treatments are limited and none of the recommended treatments target cessation of bleeding. Tranexamic acid (TXA), an antifibrinolytic agent, presents a potential option for halting bleeding in early pregnancy, potentially reducing the risk of associated adverse outcomes.
To review the current literature on the use and efficacy of TXA in early pregnancy.
A scoping review was conducted using JBI methodology. Searches were performed in Embase, Medline, CENTRAL, and grey literature. Three separate searches assessed TXA's efficacy in early pregnancy, safety profile during pregnancy, and potential teratogenicity.
Four studies met inclusion criteria for efficacy: three non-randomised prospective trials and one observational study, totaling 319 patients. Studies had small sample sizes and varied methodologies. For safety, 30 studies involving 76,302 patients were included: 13 systematic reviews/meta-analyses, 13 RCTs, 2 retrospective cohorts, 1 prospective case-control study, and 1 open-label dose-ranging study. Most focused on postpartum haemorrhage. No significant increase in venous thromboembolism was observed with TXA versus control. No case-control studies evaluated teratogenicity directly. However, 22 studies from 14 countries reported TXA use in pregnancy (not related to postpartum haemorrhage). Among 234 pregnancies exposed to TXA, 230 (98%) resulted in live births.
Evidence for TXA use in early pregnancy is limited, with small, low-quality studies. Larger, high-quality trials are needed to determine safety and efficacy.

PMID:
42667743
Bibliographic data and abstract were imported from PubMed on 30 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.